Zumutor Biologics Raises $7.3 Mn For Cancer Trials

Zumutor Biologics raised $7.3 Mn in Series B funding from Accel, Bharat Innovation Fund, Premji Invest, and angel investors. The biotech startup will use the capital to complete its US FDA Phase 1 study of ZM008, a first-in-class NK cell checkpoint therapy for solid tumors, and initiate Phase 1B and global Phase 2 studies.